An observational study in Systemic Rheumatic Diseases, Intensive Care Unit and Corticosteroids, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-05-28.
Sponsored by University Hospital, Montpellier · Observational
Critically ill systemic rheumatic disease (SRD) patients have benefited from better provision of rheumatic and critical care in recent years. Recent comprehensive data regarding in-hospital mortality and most importantly long-term outcome are scarce. The aim of this study is to assess short and long-term outcome of patients with SRD admitted to the ICU in a retrospective cohort study (2006 - 2016).
377 studies on the registry are indexed under Rheumatic Diseases; 79 are open to participants now.
This study's enrollment of 525 is above the median of 245 across 157 observational studies indexed under Rheumatic Diseases.
Browse Rheumatic Diseases studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive SRD patients admitted to ICUs during the study period
Exclusion criteria:
Mortality rate in the ICU associated risk factors
Mortality rate in the ICU associated risk factors
Time frame: 1 day
Mortality rate in the hospital and one-year after ICU admission and associated risk factors
Mortality rate in the hospital and one-year after ICU admission and associated risk factors
Time frame: 1 day
Plan to share: Undecided — NC
No publications or documents are linked to this record.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier